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Summary
Objectives: This preliminary study sought to investigate the response of uncomplicated falci-
parum infections to semi-supervised drug administration with quinine and two adjunctive
schizontocidal drugs in infected patients in Guyana. Quinine and chloroquine cross-sensitivity
was also assessed in vitro.
Methods: Patients were treated with quinine 10 mg/kg for 7 days followed by sulfadoxine/
pyrimethamine 25 mg/kg single dose (in children) or doxycycline 100 mg daily for 7 days (in
adults). Independently, falciparum-infected blood-medium mixtures were cultured in standar-
dized pre-dosed quinine and chloroquine test plates, according to the protocol of the World
Health Organization Mark III in vitro test system, for analysis.
Results: The quinine/doxycycline regimen (N = 12) produced 100% clinical cure (12/12) at day 14
and 100% parasitological cure (11/11) at day 28. However, with the quinine/sulfadoxine/
pyrimethamine scheme, 1/12 therapeutic failure (on day 14) and 2/9 parasitological failures
(on day 28) were observed. In vitro, parasite development beyond the cut-off concentrations and
high IC50 values (geometric mean IC50 quinine 504.65 nM and IC50 chloroquine 506.69 nM),
confirmed diminished Plasmodium falciparum sensitivity to both drugs.
Conclusion: These findings suggest P. falciparum resistance to both quinine and chloroquine, and
support either the use of antibiotics as adjuncts to quinine therapy or drugs with alternate
pharmacodynamics as first-line therapy.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +592 222 4925.
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Sequential drug administration has been successfully
employed to prolong drug activity in managing infectious
diseases.1 As such, in response to the consistently observed
failure of chloroquine in 1975 and subsequently, in 1978, of
sulfadoxine/pyrimethamine monotherapy to cure Plasmo-
dium falciparum infections in Guyana, a protocol for the
sequential treatment of uncomplicated infections with qui-
nine sulfate and sulfadoxine/pyrimethamine was employed
between 1984 and 2001.2,3
Guyana is a South American country (86 000 sq. miles)
with a population of approximately 721 000 persons.4 While
most of the residents live on a narrow coastal strip that is
largely devoid of active malaria transmission (Figure 1),
malaria remains endemic in the interior geopolitical regions,
i.e., Regions 1, 7, 8, and 9. In this primarily Amazonian
tropical rainforest district, the sylvatic Anopheles darlingi
is considered the primary vector for malaria transmission.5,6
Here also, the resident population is small and scattered, but
there is a sizeable itinerant group of miners and loggers that
moves not only throughout the interior and coastal areas of
Guyana, but also into the neighboring countries of Brazil,
Venezuela, and Suriname. The available healthcare facilities
are basic with no regular electricity supply, and care is
provided primarily by community health workers andmedical
extension officers (Medexes) at health centers or smaller
health posts. When possible or necessary, patients travel
to the capital city Georgetown for treatment.Figure 1 Map of Guyana showing the 10 administrative geo-
political regions and study sites.Recognizing the persistent problem of patient non-com-
pliance since the introduction of the sequential quinine
combination regimens in Guyana,7,8 and the consequent
possibility of natural selection of drug-resistant parasites
after years of variable drug pressure, this study was con-
ducted in an endemic community to gather preliminary data
on the in situ effectiveness of two treatment regimens
utilizing quinine with either sulfadoxine/pyrimethamine or
doxycycline. To identify trends in parasite responsiveness to
quinine and chloroquine, the in vitro responses of P. falci-
parum to both drugs were determined using isolates obtained
from a second group of patients who had been infected in the
same endemic areas, but who had traveled to the city for
treatment.
Methods
The protocols were approved by the Ethics Committee of the
Faculty of Medical Sciences, The University of the West
Indies, St. Augustine, Trinidad and Tobago and the Institu-
tional Review Board of the Ministry of Health, Guyana. The
studies were conducted between May and October 2001. The
clinical study was executed at the Mahdia District Hospital
(Region 8) in the interior of Guyana, while the in vitro studies
were done in the coastal capital city Georgetown at the
Vector Control Services (VCS) referral clinic of the George-
town Hospital and at the Eureka Laboratory. All patients or a
parent/guardian signed informed consent prior to participa-
tion.
Clinical study
Subjects
Owing to the exigencies associated with conducting clinical
studies in the malaria-endemic communities of Guyana, and
in the interests of time and cost, a convenient sample was
used for this preliminary study. Consenting ambulatory
residents (>6 months age) living in Mahdia for at least 6
months, with a minimum diagnosis of uncomplicated asex-
ual stage P. falciparum infection (parasite count500 para-
asites/ml blood following an initial relative parasite count
by the VCS of at least +F or 1—10 falciparum parasites per
100 thick film fields), and a recent history of fever, were
recruited consecutively into the study. Exclusion criteria9
included pregnancy (self-reported last menstrual period),
breast feeding, symptoms of severe malaria, reported cur-
rent or recent use (in the past 2—4 weeks) of quinine,
chloroquine, doxycycline, mefloquine, or halofantrine, a
positive Dill and Glazko10 urine test, and current or recent
use of herbal extracts/infusions of local herbs used to treat
symptoms of malaria. Demographic data and a recent his-
tory of malaria were collected, and after a clinical exam-
ination by the doctor or trained paramedical staff (Medex),
patients were asked to remain in the study area for 28 days
of follow-up.
Management
Patients were placed into one of two treatment groups:
adults (age 14 years) and children (age 6 months to <14
years). Based upon the national treatment schedules3 in use
at that time, patients received from the research team or a
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8 hours; Novopharm Ltd, Toronto, Canada) for 7 days. For
adults, this was followed on day 8 by doxycycline tablets
100 mg daily (International Dispensary Association, Holland)
for seven additional days, while children, received a single
sulfadoxine/pyrimethamine tablet (sulfadoxine 25 mg/kg;
International Dispensary Association, Holland) on day 8. A
single dose of primaquine 0.75 mg/kg (up to 45 mg in adults;
International Dispensary Association, Holland) was given
along with the first quinine dose in both groups of patients
as a gametocytocidal agent. Febrile patients (>37.5 8C at
enrolment) were given acetaminophen (International Dispen-
sary Association, Holland) on admission into the study, and for
subsequent self-administration if necessary. Temperature
was recorded on days 1—8, 14, 21, and 28, and Giemsa-
stained thick blood films were evaluated 24 and 48 hours
after enrollment into the study,11 and on days 4, 6, 7, 14, 21,
and 28. Reports of likely adverse effects were taken at each
visit, and patients were advised to return to the research
team if they experienced any illnesses between visits. Ther-
apeutic response to the sequential regimen was assessed on
day 14 according to World Health Organization (WHO) cri-
teria,9 while parasitologic response was determined on day
28. Since all patients were remaining in an area of ongoing
transmission, pyrethroid-treated bed-nets, mosquito coils,
and skin repellent were supplied with advice on their appro-
priate usage, to reduce the likelihood of reinfection during
the 28-day period.
Ethical considerations for withdrawal
Patients were considered for withdrawal from the study if
the initial diagnosis could not be re-confirmed by a senior
microscopist, parasitemia or symptoms worsened between
days 1 and 6, or adverse effects of drugs were intolerable. In
all cases, the patients would be referred to the VCS for
appropriate clinical assessment and completion of ther-
apy.12
In vitro study
Subjects
In Georgetown, patients were selected for the in vitro study
using the same procedure and exclusion criteria applied for
obtaining the sample for the clinical study. Patient interviews
provided information on their demographic profiles, recent
history of malaria, and use of antimalarial preparations.
Culturing of parasites
The protocol of the WHO Mark III in vitro test system13 was
employed with standardized pre-dosed chloroquine and qui-
nine test plates prepared by the Vector Control Research Unit
of the Universiti Sains Malaysia, Penang, Malaysia by arrange-
ment with the WHO Western Pacific Regional Office. All tests
were run in triplicate. After incubation, thick films of the red
blood cell precipitate were stained with 2% Giemsa solution
and the numbers of schizonts with three or more merozoites
per 200 asexual parasites were counted.
The recommended cut-off points for parasite resistance in
the WHO Mark III system,13 are growth of schizonts with three
or more nuclei at a concentration of 5.12 mmol/l (quinine)
and 12.8 mmol/l (chloroquine).Data analysis
Student’s t-test was used to compare the mean parasitemia
at enrolment of patients in both treatment arms of the
clinical study. A 95% level of significance was applied in all
tests. Confidence intervals for evaluable treatment out-
comes were computed using an online calculator (http://
www.dimensionresearch.com/resources/calculators/con-
f_prop.html). Inhibitory concentrations for each drug used in
the in vitro test were determined by non-linear regression
analysis using the HN-NonLin V1.1 computer program devel-
oped by Dr Harald Noedl for the analysis of in vitro drug
sensitivity data (http://www.who.int/malaria/rbm/Attach-
ment/20041108/NonLin_V1.1.xls). The data were graphed
following adaptation to a log-probit model. Parasite activity
to quinine and chloroquine as measured by IC50 and IC90
values was compared by using Spearman’s coefficient at
the two-tailed level of significance.
Results
Clinical findings
Although 32 patients were enrolled initially into the clinical
study, five patients were withdrawn for reasons unrelated to
the treatment protocol and an additional three were lost to
follow-up early in their treatment due to work-relatedmigra-
tion. Eventually 24 patients including 12 adults (median age
23 years) and 12 children (median age 6.5 years) were
successfully followed up for clinical resolution (14 days),
and 20 patients (11 adults and nine children) for parasitologic
resolution (28 days). There was no significant difference in
the mean parasitemia ( p = 0.24) between the two treatment
groups at recruitment.
Table 1 summarizes the results of the two treatment arms.
Among children (QPS), one patient had both clinical and
parasitologic failure (day 11 of treatment), while in another
patient, only parasitologic failure was reported, as parasi-
temia recurred on day 17 of treatment. Two intercurrent
Plasmodium vivax infections (which were censored) were
also diagnosed in this group on days 14 and 23. All of these
infections were symptomatic. The recurrent P. falciparum
and intercurrent P. vivax infections were referred to the VCS
for subsequent management. All adults (QPD) who completed
follow-up showed an adequate clinical response at day 14 and
parasitologic sensitivity up to day 28. Ringing in the ears or
deafness was the most commonly reported adverse effect
(100% of persons reporting) in the first week of therapy.
In vitro results
Of 30 persons interviewed, 23 patients infected in the ende-
mic area satisfied the inclusion criteria. Median age was 24
years and the geometric mean parasitemia at recruitment
was 7419.2 parasites/ml blood. The %SMI (schizont matura-
tion inhibition) values suggested reduced sensitivity to qui-
nine in 6/14 samples and to chloroquine in 11/14 samples,
although three of the latter were considered only borderline
resistant. Twelve samples (52%) were successfully cultured
for both quinine and chloroquine, and the assessment of their
quinine/chloroquine cross-sensitivities by correlation analy-
sis found a weak and insignificant relationship at the IC50
Table 1 Treatment outcomes (cure/failure) for both the clinical and parasitological end points measured
Treatment Day 14 (clinical) Day 28 (parasitological)
QPD (12) Adults N 12 11
Cure (95% CI) 12 11
100% (75—100) 100% (73.5—100)
Failure (95% CI) 0 0
0% (0.0—24.7) 0% (0.0—26.5)
QPS (12) Children N 12 9
Cure (95% CI) 11 7
91.7% (63.9—98.1) 77.8% (44.4—93.3)
Failure (95% CI) 1 (day 11) 2 (day 11, day 17)
8.3% (0.2—36.0) 22.2% (6.7—55.6)
QPD, quinine/primaquine/doxycycline; QPS, quinine/primaquine/sulfadoxine/pyrimethamine.
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probit graphs for quinine and chloroquine (Figure 2) in com-
parison seemed to suggest a trend to correlation between the
responses to the two drugs at the lower drug concentrations,
with quinine possibly displaying greater potency as the slope
of its regression line appeared steeper.
Discussion
Decisions to modify national treatment protocols in Guyana
have for many years been based upon clinical observations in
a range of patients. This has been as a consequence of the
unavailability of scientific data, as clinical studies following
either WHO or other established protocols were not routinely
conducted by the National Malaria Control Programme. While
clinical studies provide an opportunity to discern the degree
of therapeutic failure in the context in which it is likely to be
manifested in an endemic community, in vitro tests prefer-
entially highlight specific drug-sensitivities of parasites, and
expose subtle response trends.
In Guyana, chloroquine had been used successfully to
manage falciparum infections for many years, but was dis-
continued in the light of clinical observations and reported
spreading drug resistance in neighboring countries (Brazil,14
Suriname,15 and Venezuela16). In 2002, the clinical responses
of a group of P. vivax and P. falciparum infected Guyanese
patients given observed treatment with chloroquine was
described.8 Although providing good symptomatic relief forTable 2 In vitro indices of parasite responses to the two
drugs chloroquine and quinine showing the mean 50% and 90%
(IC50 and IC90) inhibitory concentrations for the samples and a
correlation analysis of parasite cross-sensitivities to the two
drugs
IC50 (nmol/l)
a IC90 (nmol/l)
a
Quinine (N = 14) 504.651 1526.904
Chloroquine (N = 14) 506.6914 1579.172
N (pairs Cq/Q) 12 12
R (Spearman’s) 0.190 0.529
p 0.554 0.077
Significance NS ( p > 0.05) NS ( p > 0.05)
a Geometric means of the IC50 and IC90 values. Cq, chloroquine;
Q, quinine.the patients with P. falciparum, chloroquine at that time
nevertheless produced 48% therapeutic failure by day 14 and
55% parasitologic failure by day 28. Our in vitro findings
reported here, although derived from a small sample, high-
light a similar heterogeneity of the parasite population,
featuring a mix of chloroquine sensitive and resistant para-
sites with a greater tendency towards drug resistance.
As a result of the prevalence of chloroquine resistance in
this geographic region, the possibility of a compromised
parasite response to the analog quinine, as observed in other
countries,17—19 was likely. In this context, the D1246Y,
S1034C, and N1042D pfmdr1mutations, which are associated
with quinine resistance in Brazil,17 had also been reported in
molecular studies on chloroquine-resistant isolates from
Guyana20 hinting at a relationship between parasite sensi-
tivity to these drugs. As such, activity correlation analyses
were undertaken to investigate this further.21 This prelimin-
ary study however, likely due to the small sample size, did not
find good evidence of correlation between chloroquine and
quinine activity in vitro at the IC50 level. Further the stronger
yet negative activity relationship at the IC90 level suggests
diverging mechanisms of action at higher drug concentra-
tions, and deserves to be verified in larger studies.
While the apparently waning parasite susceptibility to
quinine clinically, and the trends of the log-concentrationFigure 2 Log-probit regression curves comparing in vitro para-
site inhibition by quinine and chloroquine (SMI = schizont
maturation inhibition).
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chloroquine described here, evince similarity in the
mechanisms of resistance to the two drugs at low levels of
resistance, the presence of other influences such as inde-
pendent mechanisms of action for quinine at higher drug
levels, cannot be ignored. These observations allude to a
likely role for factors apart from the widely speculated non-
compliance7,8 in the observed failure of the quinine/sulfa-
doxine/pyrimethamine regimen to produce a clinical and
parasitologic cure consistently. The current findings also
emphasize the need to comprehensively study the drug
sensitivities of the P. falciparum parasite population in
Guyana, in an effort to support the most pharmacoeconomic
and rational choice of treatment regimens in the cash-
strapped public sector.
A major limitation of the current clinical study was the
inability to use cytogenetic studies to differentiate between
recrudescence and reinfection in the clinical cases of recur-
rent parasitemia. However if self-reported compliance with
the treatment regimen is accepted, the recurrence of symp-
toms and parasitemia within 11 days in one case while using
more than one intervention against exposure, mitigates the
likelihood of reinfection. Still the small sample sizes limit
clear conclusion of the superiority of one drug or drug regi-
men over the other, again underscoring the importance of
extending these studies to confirm the findings.
In conclusion, these preliminary findings indicate declin-
ing sensitivity of P. falciparum to quinine in Guyana. As the
use of other quinoline-related drugs (mefloquine and halo-
fantrine) spreads and new schizontocidals (artemesinin deri-
vatives) are introduced as first-line drugs for falciparum
malaria in Guyana, periodic larger clinical and in vitro studies
will be needed to inform the National Malaria Control Pro-
gramme on the dynamics of parasite cross-sensitivities within
the local population. Finally, since quinine remains the
national drug of choice for severe malaria and for the treat-
ment of both children under 5 years and pregnant women in
their first trimester however, conservation of its usefulness
must also be addressed.
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